Researchers announced on Saturday an experimental drug that significantly reduces the negative effects of heart failureSome are calling it "one of the biggest potential advances" against the disease in more than 10 years.
Currently called LCZ696, the drug is being developed by Swiss pharmaceutical company Novartis, according to a study in the New England Journal of Medicine . A release from Novartis suggested that LCZ696 cut the risk of death and hospitalization from heart failure by a fifth, and measurably improved patients' quality of life.
More about Prescription Drugs, World, Lifestyle, Health Fitness, and Heart
Comments
Post a Comment